GM 103 - GeneMedicine
Alternative Names: GM-103; GM-103 - GeneMedicineLatest Information Update: 28 Feb 2024
At a glance
- Originator GeneMedicine Co Ltd
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Angiogenesis inhibitors; Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Liver-cancer in South Korea
- 28 Feb 2024 No recent reports of development identified for preclinical development in Lung-cancer in South Korea
- 20 Feb 2024 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Monotherapy) in South Korea (Intratumoural) (NCT06265025)